Uncategorized
Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
As Sangamo runs out of cash, Eli Lilly and Astellas have emerged as stalking horse bidders for key assets, including a Fabry gene therapy currently being submitted for potential FDA approval.